

As part of this study, I am receiving treatment with:

- ☐ JNJ-79635322 (BCMA x GPRC5D x CD3 Tri Specific Antibody for Multiple Myeloma)
- ☐ Teclistamab (TECVAYLI)

If presenting for emergent treatment, please consider assessment for possible Cytokine Release Syndrome (CRS) and/ or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) as part of initial patient assessment.

Due to the potential seriousness of CRS/ICANS, all attempts should be made to medically assess the patient as soon as possible upon arrival to your medical facility. For more information, please contact treating physician or study sponsor at the numbers listed on this card.

Johnson & Johnson

**CARD FOR CLINICAL
STUDY PARTICIPANT**

*Global Version 1.0 09/JAN/2026
Country Version 1.0 18/Feb/2026*

PARTICIPANT CARD

Always present this card whenever you visit your Physician or a Hospital or in case of an EMERGENCY.

Participant's Name

Doctor in charge

Study Number **79635322MMY3002**

Hospital

Department

Site Number

Participant Number

24h emergency contact

This is a clinical study participant. If you are a healthcare professional and information is required about the study or study drug, please contact the investigator.

Local Sponsor ☎: 000 80005 01161

Please call the local sponsor only if you are unable to reach the investigator and in case of emergency. Please do not provide your personal data, only the subject number.